PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

Evolocumab prevents carotid artery wall thickening in paediatric HeFH PCSK9 plays critical role in abdominal aortic aneurysm Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid PCSK9 inhibitors are unlikely to contribute to mood disorders PCSK9 inhibitors may be effective treatment for PAD

Latest News Updates

13th Closed Scientific Expert Meeting of the Editorial Board

Virtual meeting, 1st and 8th October 2020 (Educational supporters)

Keynote – Post CVD event depression: The prequel and sequel

Keynote – Post CVD event depression: The prequel and sequel

Reports from the 13th Closed Virtual Expert Meeting of the PCSK9 Education and Research Forum Prof David Hare

Posted on 3 December 2020 | Posted in 13th Closed Scientific Expert Meeting of the Editorial Board

LDL-cholesterol: “The times are a-changin”

LDL-cholesterol: “The times are a-changin”

Reports from the 13th Closed Virtual Expert Meeting of the PCSK9 Education and Research Forum Prof Alan Remaley

Posted on 23 November 2020 | Posted in 13th Closed Scientific Expert Meeting of the Editorial Board

Keynote – Lipoprotein(a): “The proof of the pudding is in the trial”

Keynote – Lipoprotein(a): “The proof of the pudding is in the trial”

Reports from the 13th Closed Virtual Expert Meeting of the PCSK9 Education and Research Forum Professor Joe Witztum

Posted on 20 November 2020 | Posted in 13th Closed Scientific Expert Meeting of the Editorial Board

Cost-effectiveness of PCSK9 inhibitors: A coming of age?

Cost-effectiveness of PCSK9 inhibitors: A coming of age?

Reports from the 13th Closed Virtual Expert Meeting of the PCSK9 Education and Research Forum Dr. Kirsten Bibbins-Domingo & Prof. Dhruv S. Kazi

Posted on 30 October 2020 | Posted in 13th Closed Scientific Expert Meeting of the Editorial Board

A target level for LDL-C in secondary prevention: What have we learned from PCSK9 inhibitor trials?

A target level for LDL-C in secondary prevention: What have we learned from PCSK9 inhibitor trials?

Reports from the 13th Closed Virtual Expert Meeting of the PCSK9 Education and Research Forum Gregory Schwartz

Posted on 21 October 2020 | Posted in 13th Closed Scientific Expert Meeting of the Editorial Board

LDL subclasses, bioactive lipids and atherogenicity: Impact of statin action

LDL subclasses, bioactive lipids and atherogenicity: Impact of statin action

Reports from the 13th Closed Virtual Expert Meeting of the PCSK9 Education and Research Forum Professor John Chapman

Posted on 21 October 2020 | Posted in 13th Closed Scientific Expert Meeting of the Editorial Board

COVID-19 infection and cardiovascular events

COVID-19 infection and cardiovascular events

Reports from the 13th Closed Virtual Expert Meeting of the PCSK9 Education and Research Forum Professor Gilles Montalescot

Posted on 21 October 2020 | Posted in 13th Closed Scientific Expert Meeting of the Editorial Board

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation

LIB Therapeutics

Novartis

Sanofi

© Copyright 2025 PCSK9 Forum. All rights reserved